Literature DB >> 8044834

Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells.

W Herr1, T Wölfel, M Heike, K H Meyer zum Büschenfelde, A Knuth.   

Abstract

A limiting-dilution assay was developed and used to determine the frequency of autologous tumor-reactive cytotoxic T lymphocytes (CTL) in peripheral blood of a melanoma patient MZ2, who has been free of detectable disease since several years. In this patient, the frequencies of tumor-reactive CTL spontaneously varied only by a factor of 1.5. After vaccinations with autologous mutagenized and lethally irradiated tumor cells a two- to tenfold increase in frequencies of tumor-reactive CTL was found within the first 2 weeks. Thereafter, CTL frequencies returned to values measured prior to vaccinations. We conclude, that the limiting-dilution assay applied in this study can detect changes in the T cell response to autologous tumor cells. The frequency of tumor-reactive CTL determined with this approach can serve as an immunological parameter for monitoring the T cell response to autologous tumor cells in individual cancer patients receiving tumor cell vaccinations.

Entities:  

Mesh:

Year:  1994        PMID: 8044834     DOI: 10.1007/bf01525314

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Analysis of cytotoxic T cell precursor frequencies directed against individual HLA-A and -B alloantigens.

Authors:  L Zhang; S G Li; B Vandekerckhove; A Termijtelen; J J Van Rood; F H Claas
Journal:  J Immunol Methods       Date:  1989-07-06       Impact factor: 2.303

2.  Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones.

Authors:  G Degiovanni; T Lahaye; M Hérin; P Hainaut; T Boon
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

3.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans.

Authors:  A Hoffenbach; P Langlade-Demoyen; G Dadaglio; E Vilmer; F Michel; C Mayaud; B Autran; F Plata
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

Review 4.  Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?

Authors:  G Parmiani; A Anichini; G Fossati
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

Review 5.  Defined antigens recognized by T lymphocytes on human tumors.

Authors:  P G Coulie; A Van Pel
Journal:  Curr Opin Oncol       Date:  1993-11       Impact factor: 3.645

6.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

7.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

8.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

9.  Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line.

Authors:  T Boon; O Kellermann
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

10.  Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations.

Authors:  A Moretta; G Pantaleo; L Moretta; M C Mingari; J C Cerottini
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  9 in total

Review 1.  [Prostate carcinoma: vaccination as a new option for treatment].

Authors:  J Bedke; C Gouttefangeas; A Stenzl
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

2.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

4.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

Review 5.  Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.

Authors:  D Jäger; E Jäger; A Knuth
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

6.  Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.

Authors:  E Jäger; D Jäger; J Karbach; Y T Chen; G Ritter; Y Nagata; S Gnjatic; E Stockert; M Arand; L J Old; A Knuth
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

7.  High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Authors:  Catherine Germeau; Wenbin Ma; Francesca Schiavetti; Christophe Lurquin; Emmanuelle Henry; Nathalie Vigneron; Francis Brasseur; Bernard Lethé; Etienne De Plaen; Thierry Velu; Thierry Boon; Pierre G Coulie
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

8.  Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

Authors:  P Möller; Y Sun; T Dorbic; S Alijagic; A Makki; K Jurgovsky; M Schroff; B M Henz; B Wittig; D Schadendorf
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 9.  Dendritic cell vaccination and immune monitoring.

Authors:  E H J G Aarntzen; C G Figdor; G J Adema; C J A Punt; I J M de Vries
Journal:  Cancer Immunol Immunother       Date:  2008-07-10       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.